Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men

Clinical Endocrinology

Volumn 75, Issue 6, 2011, Pages 836-843

  Wang, Christina ^a   Ilani, Niloufar ^a   Arver, Stefan ^b   McLachlan, Robert I ^c   Soulis, Tina ^d   Watkinson, Adam ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d Acrux Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; APPENDICITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; ARTICLE; AXILLA; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SOLUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEPATITIS C; HUMAN; LABORATORY TEST; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOOD CHANGE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RHINOPHARYNGITIS; SEXUAL FUNCTION; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; VOMITING;

ADMINISTRATION, TOPICAL; ADULT; AFFECT; AGED; ANDROGENS; AXILLA; CHEMISTRY, PHARMACEUTICAL; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; TESTOSTERONE; TREATMENT OUTCOME;

EID: 80855156741     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04152.x     Document Type: Article

References (27)

1. Nieschlag, E., Behre, H.M., Bouchard, P., et al. (2004) Testosterone replacement therapy: current trends and future directions. Human Reproduction Update, 10, 409-419. (Pubitemid 39232796)
2. Bhasin, S., Cunningham, G.R., Hayes, F.J., et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 95, 2536-2559.
3. Darby, E., &, Anawalt, B.D., (2005) Male hypogonadism: an update on diagnosis and treatment. Treatments in Endocrinology, 4, 293-309. (Pubitemid 43126997)
4. Arver, S., Dobs, A.S., Meikle, A.W., et al. (1997) Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clinical Endocrinology, 47, 727-737. (Pubitemid 28046562)
5. Jordan, W.P. Jr, (1997) Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. American Journal of Contact Dermatitis, 8, 108-113. (Pubitemid 27237125)
6. Steidle, C., Schwartz, S., Jacoby, K., et al. (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism, 88, 2673-2681. (Pubitemid 36724441)
7. Wang, C., Swerdloff, R.S., Iranmanesh, A., et al. (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 85, 2839-2853. (Pubitemid 32269162)
8. Alberti, I., Grenier, A., Kraus, H., et al. (2005) Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opinion on Drug Delivery, 2, 935-950. (Pubitemid 41488851)
9. Jordan, W.P. Jr, Atkinson, L.E., &, Lai, C., (1998) Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clinical Therapeutics, 20, 80-87. (Pubitemid 28126282)
10. Ainbinder, D., &, Touitou, E., (2005) Testosterone ethosomes for enhanced transdermal delivery. Drug Delivery, 12, 297-303. (Pubitemid 41356186)
11. Lee, K.K., Berman, N., Alexander, G.M., et al. (2003) A simple self-report diary for assessing psychosexual function in hypogonadal men. Journal of Andrology, 24, 688-698. (Pubitemid 38133070)
12. Turner-Bowker, D.M., Bartley, P.J., &, Ware, J.E. Jr, (2002) SF-36 Health Survey & ''SF'' Bibliography, 3rd edn. QualityMetric Incorporated, Lincoln, RI.:13.
13. Olsen, C., (1991) Evaluation of the dermal irritancy of chemicals. In:, D.W. Hobson, ed. Dermal and Ocular Toxicology Fundamentals and Method. CRC Press, Boca Raton, FL, 130-131.
14. Nicolazzo, J.A., Morgan, T.M., Reed, B.L., et al. (2005) Synergistic enhancement of testosterone transdermal delivery. Journal of Controlled Release, 103, 577-585. (Pubitemid 40471016)
15. Sunscreen drug products for over-the-counter human use: final monograph. (1999) 64 Federal Register: 27666-27693 (codified at 21 CFR Parts 310, 352, 700, and 740).
16. Therapeutic Goods Administration. Australian regulatory guidelines for OTC medicines (ARGOM) [internet]. Available from:. Accessed March 23, 2011.
17. In vitro diagnostic medical devices. European Commission Directive 1998 (98/79/EC).
18. Sunburn protectants. Health Canada, 2006 [internet]. Available from: mps/prodnatur/applications/licen-prod/monograph/mono-sunprotect-ecransolaire- eng.php. Accessed March 23, 2011.
19. Japan Ministry of Health and Welfare Notification Number 331; 2000.
20. Cavender, R.K., &, Fairall, M., (2011) Precocious puberty secondary to topical testosterone transfer: a case report. Journal of Sexual Medicine, 8, 622-626.
21. Marjason, J., Watkinson, A., &, Soulis, T., (2011) Evaluation of the amount of residual testosterone topical solution 2% remaining on the underarm in healthy males who undergo post-dose washing procedures. Journal of Andrology, 32 (Suppl. Mar/April 2011, abstract number 74), 77.
22. Vermeulen, A., Verdonck, L., &, Kaufman, J.M., (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism, 84, 3666-3672. (Pubitemid 30645223)
23. Wang, C., Swerdloff, R., Kipnes, M., et al. (2004) New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 89, 3821-3829. (Pubitemid 39071479)
24. Dobs, A.S., Meikle, A.W., Arver, S., et al. (1999) Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 84, 3469-3478. (Pubitemid 30645193)
25. Wang, C., Berman, N., Longstreth, J.A., et al. (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. Journal of Clinical Endocrinology & Metabolism, 85, 964-969. (Pubitemid 32269334)
26. Fernàndez-Balsells, M.M., Murad, M.H., Lane, M., et al. (2010) Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 95, 2560-2575.
27. Calof, O.M., Singh, A.B., Lee, M.L., et al. (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 60, 1451-1457. (Pubitemid 41798454)